Dr. Agarwal's Health Care IPO analysis

Dr. Agarwal's Health Care IPO (initial public offering) will open for subscription on January 29, 2025, and close on January 31, 2025. Below is a breakdown of the eye specialist's strengths, weaknesses and growth prospects to help investors make an informed decision.

Dr. Agarwal's Health Care IPO in a nutshell

• Quality: Between FY22 and FY24, Dr. Agarwal's Health Care reported a three-year average ROE and ROCE of around 18 and 11 per cent, respectively.
  
• Growth: Between FY22 and FY24, its revenue and net profit grew annually by 38 per cent and 48 per cent, respectively.
  
• Valuation: At the upper price band of Rs 402, the stock is expected to be valued at a P/E and P/B ratio of around 123.3 and 7 times, respectively.
  
• Overview: India has the largest number of visually impaired people worldwide, making eye care a critical sector. The Indian eye care market, which constituted about 6 per cent of the overall healthcare market in FY24, is projected to grow at 12-14 per cent annually between 2024 and 2028. However, interested investors should take note of the high competitive intensity of the eye care market.

About Dr. Agarwal's Health Care

Incorporated in 2010, Dr. Agarwal's Health Care is an eye care service provider specialising in surgical procedures (cataract and refractive), consultations, diagnostics, and the sale of eye-related products. The eye specialist derives 65 per cent of its revenue from the surgery segment and 21 per cent from product sales. It currently has 737 doctors and derives nearly 90 per cent of its revenue from India.

It operates on a 'hub and spoke' model, where central facilities (hubs) handle complex medical procedures, while smaller facilities (spokes) manage basic care and refer patients needing specialised treatment to the hubs. As of FY24, Dr. Agarwal's Health Care operates 28 hubs and 165 spokes across India and holds a 25 per cent market share in the country's eye care service chain market.

Strengths of Dr. Agarwal's Health Care

• Comprehensive service offerings: Dr. Agarwal's Health Care offers end-to-end eye care services, covering everything from checkups and consultations to surgeries and the sale of optical and pharmaceutical products. Patients can conveniently access all eye-related services under a single brand.
  
• Dominant market position: The company is India's largest eye care service provider by revenue, commanding a 25 per cent market share of the eye care service chain market.

Weaknesses of Dr. Agarwal's Health Care

• Geographic concentration: As of September 30, 2024, almost 50 per cent of the company's facilities are concentrated in Tamil Nadu and Maharashtra. This reliance on two states exposes it to risks such as economic disruptions, political or social unrest, or changes in state-specific policies that could impact its financials.
  
• Intense competition: The Indian eye care market is highly competitive, with the presence of established single-specialty players like ASG Hospitals, Centre for Sight, Lotus Eye Hospitals and Disha Eye Hospitals, along with numerous multi-specialty healthcare providers.

Risk report

Company and business

• Did Dr. Agarwal's Health Care report earnings before tax of Rs 50 crore or more in the last 12 months?
  Yes. The company reported earnings before tax of Rs 151 crore for 12 months ending September 2024.
  
• Will the company be able to scale up its business?
  Yes. The Indian eye care industry is projected to grow at 12-14 per cent annually between FY24 and FY28, indicating a favourable market environment that could support the company's growth.
  
• Does the company have recognisable brands with client stickiness?
  Yes. Dr. Agarwal's Health Care is India's largest eye care service provider (in terms of revenue), which suggests a strong market presence and brand recognition.
  
• Does the company have a credible moat?
  No. The Indian eye care industry is highly competitive, with many public hospitals, private hospitals and eye clinics vying for market share.

Management

• Do any of the company's founders still hold at least a 5 per cent stake? Or do promoters hold over a 25 per cent stake in the company?
  Yes. After the IPO, the promoters will have a 32.5 per cent stake in the company.
  
• Do the top three managers have over 15 years of combined leadership at Dr. Agarwal's Health Care?
  Yes. Adil Agarwal, full-time director and CEO, has been with the company since its incorporation in 2010.
  
• Is the management trustworthy? Is it transparent in its disclosures, which are consistent with SEBI guidelines?
  Yes. There is no information to suggest otherwise.
  
• Is the company's accounting policy stable?
  Yes. There is no information to suggest otherwise.
  
• Is Dr. Agarwal's Health Care free of promoter pledging of its shares?
  Yes. The promoters have not pledged their shares.

Financials

• Did Dr. Agarwal's Health Care generate a current and three-year average return on equity of more than 15 per cent and a return on capital employed of more than 18 per cent?
  No. It has a three-year average ROE and ROCE of around 18 and 11 per cent, respectively. In FY24, it reported an ROE and ROCE of nearly 10 per cent.
  
• Was the company's operating cash flow positive during the last three years?
  Yes. It reported positive cash flow from operations during the last three years.
  
• Is the company's net debt-to-equity ratio less than one?
  Yes. As of September 30, 2024, the company's net debt-to-equity ratio stood at 0.6 times.
  
• Is the company free from reliance on huge working capital for day-to-day affairs?
  Yes. Dr. Agarwal's Health Care operates with a negative working capital cycle of 115 days. It pays suppliers in over five months and collects payments from customers within a month.
  
• Can the company run its business without relying on external funding in the next three years?
  Yes. Dr. Agarwal's Health Care is profitable and has a positive cash flow. It appears capable of operating without needing external funding for the next three years.
  
• Is the company free from meaningful contingent liabilities?
  Yes. The company's contingent liabilities stood at 2 per cent of its net worth as of Q2 FY25.

Valuations

• Does the stock offer an operating earnings yield of more than 8 per cent on its enterprise value?
  No. The stock offers an operating earnings yield of 2 per cent on its enterprise value.
  
• Is the stock's price-to-earnings less than its peers' median level?
  No. The stock is valued at a P/E ratio of 123.3 times compared to its peers' median level of 70 times.
  
• Is the stock's price-to-book value less than its peers' average level?
  Yes. The stock is valued at a P/B ratio of 7 times compared to its peers' average level of 9.5 times.

Assessing an IPO requires a careful evaluation of a company's strengths, weaknesses, and growth potential, just like we've outlined for Dr. Agarwal's Health Care. But wealth creation can only be achieved through a well-researched, balanced stock portfolio.

Our Value Research Stock Advisor can help with that. What do you get? Meticulously researched stock recommendations and ready-to-invest portfolios, updated every month. Subscribe to Value Research Stock Advisor today and take charge of your financial future.

Disclaimer: This story is not a stock recommendation. Investors should do their due diligence before investing.

Also watch: Should you invest in IPOs?